Latest News | Lupin Gets USFDA Nod for Generic Ganirelix Acetate Injection

New Delhi, Nov 17 (PTI) Pharma major Lupin Ltd on Friday said it has received approval from the US health regulator to market its generic Ganirelix Acetate injection used for hormone response regulation in women undergoing treatment for infertility.

The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Ganirelix Acetate injection of strength 250 mcg/0.5 mL single-dose prefilled syringe, Lupin said in a regulatory filing.

Also Read | Chhattisgarh Assembly Elections 2023 Phase 2: When Is Voting and Result? How To Vote, Check Name in Voter List? How To Find Polling Station? Know Everything Here.

The injection is a generic equivalent to the reference listed drug (RLD) Ganirelix Acetate Injection in strength of 250 mcg/0.5 mL of Organon USA LLC.

The product will be manufactured at Lupin's Nagpur facility in India, it added.

Also Read | Cyclone Midhili Update by IMD: Deep Depression Over Bay of Bengal Likely To Intensify Into Cyclonic Storm and Cause Heavy Rainfall in Tamil Nadu and Kerala.

Ganirelix Acetate injection had estimated annual sales of USD 84 million in the US, Lupin said citing IQVIA MAT September 2023 data.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)